Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Ivanovska, Irena ^a,d   Zhang, Chunsheng ^a,d   Liu, Angela M ^b,c   Wong, Kwong F ^c   Lee, Nikki P ^b   Lewis, Patrick ^a   Philippar, Ulrike ^d   Bansal, Dimple ^d   Buser, Carolyn ^d   Scott, Martin ^d   Mao, Mao ^a,e   Poon, Ronnie T P ^b   Fan, Sheung Tat ^b   Cleary, Michele A ^a,d   Luk, John M ^b,c   Dai, Hongyue ^a,d  

^a ROSETTA INPHARMATICS   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d MERCK RESEARCH LABORATORIES   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SCATTER FACTOR RECEPTOR; WNT PROTEIN; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MODEL; DOWN REGULATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; METABOLISM; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; CYTOLOGY; FEMALE; GENETICS; LIVER; LIVER TUMOR; MALE; PATHOLOGY; SURVIVAL;

ANIMALIA; HEPATITIS B VIRUS; HEPATITIS C VIRUS; MUS MUSCULUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 80052841535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024582     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Poon RT, Fan ST, (2004) Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 10: S39-45.
3. Hao K, Luk JM, Lee NP, Mao M, Zhang C, et al. (2009) Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9: 389.
4. Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM, (2007) Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomarkers in medicine 1: 273-284.
5. Sun S, Lee NP, Poon RT, Fan ST, He QY, et al. (2007) Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver international: official journal of the International Association for the Study of the Liver 27: 1021-1038.
6. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, et al. (2011) AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30: 1229-1240.
7. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
8. Sun S, Poon RT, Lee NP, Yeung C, Chan KL, et al. (2010) Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (
9. Luk JM, Liu AM, (2011) Proteomics of hepatocellular carcinoma in Chinese patients. Omics: a journal of integrative biology 15: 261-266.
10. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, et al. (2007) Genetics of hepatocellular carcinoma. World J Gastroenterol 13: 2271-2282.
11. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
12. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, et al. (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-864.
13. Liu AM, Xu MZ, Chen J, Poon RT, Luk JM, (2010) Targeting YAP and Hippo signaling pathway in liver cancer. Expert opinion on therapeutic targets 14: 855-868.
14. Liu LX, Lee NP, Chan VW, Xue W, Zender L, et al. (2009) Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 50: 1453-1463.
15. Frese KK, Tuveson DA, (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
16. Sweet-Cordero A, Tseng GC, You H, Douglass M, Huey B, et al. (2006) Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 45: 338-348.
17. Hui CK, Lau E, Wu H, Monto A, Kim M, et al. (2006) Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 35: 185-192.
18. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM, (2001) Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153: 1023-1034.
19. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, et al. (2007) Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 104: 14771-14776.
20. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC, (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26: 2166-2176.
21. Whiteside TL, (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
22. Midorikawa Y, Makuuchi M, Tang W, Aburatani H, (2007) Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 13: 1487-1492.
23. Lee JS, Thorgeirsson SS, (2006) Comparative and integrative functional genomics of HCC. Oncogene 25: 3801-3809.
24. Luk JM, Burchard J, Zhang C, Liu AM, Wong KF, et al. (2011) DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stem-like subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem In Press.
25. Yi X, Luk JM, Lee NP, Peng J, Leng X, et al. (2008) Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 7: 315-325.
26. Lamb JR, Zhang C, Xie T, Wang K, Zhang B, et al. (2011) Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting. PloS one 6: e20090.
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
28. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, et al. (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11: 358-365.
29. Tamayo P, Scanfeld D, Ebert BL, Gillette MA, Roberts CW, et al. (2007) Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci U S A 104: 5959-5964.
30. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
31. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101: 6062-6067.
32. Gille C, Bolling C, Hoppe A, Bulik S, Hoffmann S, et al. (2010) HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol 6: 411.
33. Jerby L, Shlomi T, Ruppin E, (2010) Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol 6: 401.
34. Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, et al. (2008) New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal 1: ra12.
35. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, et al. (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 48: 780-791.
36. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, et al. (2009) Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res 69: 1368-1374.
37. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, et al. (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306-1311.
38. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, et al. (1994) Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 91: 822-826.
39. Nishida N, Fukuda Y, Kokuryu H, Toguchida J, Yandell DW, et al. (1993) Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 53: 368-372.
40. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, et al. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582-1595.
41. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, et al. (2010) microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 6: 402.